Inclusion on the list of medicines reimbursed by National Insurance (boxes of 30 and 90) and approved for use by hospitals (boxes of 30, 50 and 90).
-
Clinical Benefit
Substantial
The actual benefit of AXELER products is substantial.
Clinical Added Value
no clinical added value
AXELER 20 mg/5 mg, 40 mg/5 mg and 40 mg/10 mg fixed-dose combinations of olmesartan medoxomil 20 or 40 mg and amlodipine besilate 5 or 10 mg provide no improvement in actual benefit (IAB V) in comparison with concurrent use of the two active substances taken separately.
Listen
